Founded in 2021, Cellogen Therapeutics operates in Health Tech offering advanced cellular engineering methods and gene therapy-based approaches to find curative treatments for various hematological ma...
Funding stage:
Undisclosed
Last funding:
17/05/2026
Total funding:
$3.81 Mn+
Revenue:
Investors
Cellogen Therapeutics: Cap Table Highlights
A snapshot of cap table and shareholder metrics
Total Shareholders8
Latest Filing Date02 Nov 2025- Funding Events11
Event-Based View
Event-Based detailed View by Filings
FAQs on Cap Table of Cellogen Therapeutics
As of 03 November 2025, Cellogen Therapeutics's equity is held by 8 shareholders, with the top three being Vasugamani Sengottian, Tanveer Ahmad, and Gaurav Kharya.
Vasugamani Sengottian holds the largest stake in Cellogen Therapeutics at 28.3% as of 03 November 2025.
As of 03 November 2025, founders collectively hold 19.0% equity in Cellogen Therapeutics.
As of 03 November 2025, investors collectively hold 1.1% equity in Cellogen Therapeutics.
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links